10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Ganciclovir

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Ganciclovir

Ganciclovir

Class : C

Show all info

Print

Contact us

  1. Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother. 2009;53(7):3017-23.

  2. Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N; Valganciclovir Solid Organ Transplant Study Group. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid-organ transplant recipients. Clin Pharmacokinet. 2005;44(5):495-507.

  3. Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Heaton N; Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation . 2004;8(12):1765-73.

  4. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver transpl. 2007;13(12):1703-09.

  5. Cymevene (ganciklovir). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-04-22, cited 2020-05-06].

  6. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother. 2009;53(7):3017-23.
  2. Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N; Valganciclovir Solid Organ Transplant Study Group. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid-organ transplant recipients. Clin Pharmacokinet. 2005;44(5):495-507.
  3. Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Heaton N; Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation . 2004;8(12):1765-73.
  4. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver transpl. 2007;13(12):1703-09.
  5. Cymevene (ganciklovir). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-04-22, cited 2020-05-06].
  6. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]